Biotechnology
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars bus...
2022-02-28 22:15
2828
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
SYDNEY, Feb. 28, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in combination with metformin and a ketogenic diet for the treatmen...
2022-02-28 21:00
2457
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the sup...
2022-02-27 18:30
4417
Jean-Luc Herbeaux to become Hovione CEO
LISBON, Portugal, Feb. 25, 2022 /PRNewswire/ -- Hovione today announced that
the Board of Directors and the shareholders have approved the appointment of
Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective1st April
2022.
2022-02-25 22:00
2997
PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial
DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (me...
2022-02-25 21:00
2334
Fosun Foundation's First Batch of 250,000 Sets of COVID-19 Rapid Antigen Test Kits Arrives in Hong Kong
HONG KONG, Feb. 25, 2022 /PRNewswire/ -- In an effort to support Hong Kong's fight against the severe fifth wave of COVID-19 epidemic, Fosun Foundation announced last week the donation ofHK$10 million anti-epidemic materials, including COVID-19 rapid antigen test kits and face masks toHong Kong. ...
2022-02-25 12:33
4550
Prenetics Partners with ACON Bio to Launch Flowflex(TM) COVID-19 Home Antigen Test in Hong Kong - the Most Accurate Test in the Market
Most Accurate Based on 2 Independent Validation Studies Across 53 Antigen Test Kits*
* To ensure accessibility, the United States FDA EUA authorized test will be
one of the most affordable tests in the market atHKD60
* Flowflex™ will be available on projectscreen.co
2022-02-25 09:53
4547
Insilico Announces Successful Completion of Phase 0 Microdose Trial and Initiates Phase I Clinical Trial for its First AI-discovered Anti-fibrotic Product Candidate with Novel Target
NEW YORK and HONG KONG, Feb. 25, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in a Phase I clinical trial evaluating ISM001-055, the first anti-fibroti...
2022-02-25 00:00
3753
SeekIn Receives CE Mark Approval for SeekInCare® Pan Cancer Early Detection Test
SHENZHEN, China, Feb. 24, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for SeekInCare® Cancer Detection Kit and is now ready to launch this test in European markets. Nearly 10 mill...
2022-02-24 21:34
1759
Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China
BEIJING, SHANGHAI and BOSTON, Feb. 23, 2022 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combinationtherapy with Cetuximab at Peking University Cancer Hospital recently. JAB-21822 in combination with ce...
2022-02-24 10:32
1639
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
TAIPEI, Feb. 23, 2022 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), aTaiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and ...
2022-02-23 23:00
2140
Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III trial with ORL-101 in patients with Leukocyte Adhesion Deficiency Type II ("LAD-II"). Orpha Labs AG is w...
2022-02-23 21:27
2215
Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results
HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial result...
2022-02-23 20:00
2156
Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced interim data from a Phase II clinical trial of STP705, a siRNA (small interfering RNA) therapeutic, ...
2022-02-23 17:53
2663
World BioEconomy Forum talks on climate - live from Ruka!
RUKA, Finland, Feb. 23, 2022 /PRNewswire/ -- The World BioEconomy Forum season 2022 has begun and it will be culminated in the annual conference in Ruka, Finland on 07 - 09 September 2022. The season will pave the way for the first bioeconomy conference to take place after the Northern Hemisphere ...
2022-02-23 16:00
3373
BIORCHESTRA Announces 45 Million USD Series C Fundraising
SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using its proprietary RNA-based drug and drug delivery platforms. Today, BIORCHESTRA announced the completion of its45 million USD (54 billio...
2022-02-23 11:26
1630
RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company
SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- RosVivo Therapeutics, Inc. (hereinafter referred to as "RosVivo") announced that it has signed a Material Transfer Agreement (MTA) with one of the largest global pharmaceutical companies Eli Lilly and Company (hereinafter referred to as "Eli Lilly...
2022-02-22 20:52
2956
Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform
SUZHOU, China, and PALO ALTO, Calif., Feb. 22, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
2022-02-22 20:30
1955
Revotek Receives Clearance from the National Health Commission of China for the World First Clinical Trial for 3D Bioprinted Stem Cell Vascular Grafts
CHENGDU, China, Feb. 21, 2022 /PRNewswire/ -- Revotek announced that it has
received clearance from the National Health Commission ofChina to begin a
clinical study in the West China Hospital,Chengdu, with its first stem cell 3D
bioprinting product, REVOVAS.
2022-02-21 22:30
1637
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer
SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment ofAlmira Chabi, M.D. as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International (HPI), a U.S. entity wholly owned by HanAll Biopharma, to strengt...
2022-02-21 22:00
2043
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9271
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7748